Intest Res Search

CLOSE


‘Intestinal Research’ (Intest Res) is the joint official publication of the Asian Organization for Crohn's and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn's Foundation (India) (CCF, india).
The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance.As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines.

Review

December 1, 2020


Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Intest Res. 2021;19(4):360-364.

Review

November 25, 2020


Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intest Res. 2021;19(4):365-378.

Review

November 6, 2020


An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, et al.
Intest Res. 2021;19(4):379-385.

Original Article

December 1, 2020


Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.
Intest Res. 2021;19(4):386-397.

Original Article

November 20, 2020


Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, et al.
Intest Res. 2021;19(4):398-407.

Original Article

November 20, 2020


Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, et al.
Intest Res. 2021;19(4):408-418.

Original Article

November 10, 2020


Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, et al.
Intest Res. 2021;19(4):419-429.

Original Article

November 9, 2020


Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, et al.
Intest Res. 2021;19(4):430-437.

Original Article

November 6, 2020


High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, et al.
Intest Res. 2021;19(4):438-447.

Original Article

August 18, 2020


Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, et al.
Intest Res. 2021;19(4):448-460.

Original Article

August 18, 2020


Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, et al.
Intest Res. 2021;19(4):461-467.

Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
Intest Res. 2021;19(4):357-359.

Editorial

Epub October 26, 2021

Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Intest Res. 2021;19(4):360-364.

Review

Epub December 1, 2020

Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intest Res. 2021;19(4):365-378.

Review

Epub November 25, 2020

An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, et al.
Intest Res. 2021;19(4):379-385.

Review

Epub November 6, 2020

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.
Intest Res. 2021;19(4):386-397.

Original Article

Epub December 1, 2020

Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, et al.
Intest Res. 2021;19(4):398-407.

Original Article

Epub November 20, 2020

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, et al.
Intest Res. 2021;19(4):408-418.

Original Article

Epub November 20, 2020

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, et al.
Intest Res. 2021;19(4):419-429.

Original Article

Epub November 10, 2020

Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, et al.
Intest Res. 2021;19(4):430-437.

Original Article

Epub November 9, 2020

High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, et al.
Intest Res. 2021;19(4):438-447.

Original Article

Epub November 6, 2020

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, et al.
Intest Res. 2021;19(4):448-460.

Original Article

Epub August 18, 2020

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, et al.
Intest Res. 2021;19(4):461-467.

Original Article

Epub August 18, 2020

Hydroxyurea associated ileocecal valve ulcer: evidence for causality
Thevaraajan Jayaraman, Ruveena Bhavani Rajaram, Gin Gin Gan, et al.
Intest Res. 2021;19(4):468-471.

Case Report

Epub December 1, 2020

Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
Eun Sil Kim, Ji Hyung Park, Yon Ho Choe, et al.
Intest Res. 2021;19(4):472-477.

Case Report

Epub October 29, 2020

Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, et al.
Intest Res. 2021;19(4):478-481.

Brief Communcation

Epub October 26, 2021

An elderly woman with severe enteritis mimicking infectious enteritis
Kazunori Nagashima, Takashi Kato, Taichi Kimura, et al.
Intest Res. 2021;19(4):482-484.

Image of the issue

Epub July 3, 2020

  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD

ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2021 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next
Close layer
prev next